Shanghai Pharmaceuticals Holding Co (2607) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2607 Analyst Ratings

Moderate Buy

4 Buy

0 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Shanghai

Pharmaceuticals Holding Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2607 Stock 12 Month Forecast

Average Price Target

HK$14.07

▲(18.01% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Shanghai Pharmaceuticals Holding Co in the last 3 months. The average price target is HK$14.07 with a high forecast of HK$14.99 and a low forecast of HK$12.10. The average price target represents a 18.01% change from the last price of HK$11.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","12":"HK$12","15":"HK$15","10.5":"HK$10.5","13.5":"HK$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.9941710813573,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$14.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.0671024018,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$14.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.095298005628223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$12.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,10.5,12,13.5,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,11.962628544719793,12.215257089439586,12.467885634159376,12.720514178879169,12.973142723598961,13.225771268318754,13.478399813038546,13.731028357758339,13.983656902478131,14.236285447197922,14.488913991917714,14.741542536637507,{"y":14.9941710813573,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,11.891315569369231,12.072631138738462,12.253946708107692,12.435262277476923,12.616577846846154,12.797893416215384,12.979208985584616,13.160524554953847,13.341840124323078,13.523155693692308,13.704471263061539,13.88578683243077,{"y":14.0671024018,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,11.739638308125249,11.769276616250497,11.798914924375744,11.828553232500992,11.85819154062624,11.887829848751489,11.917468156876735,11.947106465001983,11.976744773127232,12.00638308125248,12.036021389377726,12.065659697502975,{"y":12.095298005628223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.643,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.643,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.787,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.683,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.293,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.475,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.027,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.345,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.397,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$14.99

Average Price TargetHK$14.07

Lowest Price TargetHK$12.10

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Citi

Not Ranked

Citi

HK$14.2

Buy

19.13%

Upside

Reiterated

11/03/25

Citi Sticks to Their Buy Rating for Shanghai Pharmaceuticals Holding Co (SHPMF)

Owen Mediport

TR | OpenAI - 4o

HK$13.5→HK$13

Buy

9.06%

Upside

Reiterated

11/01/25

AI Generated ArticleAI Generated Article

Unknown Analyst

CICC

Not Ranked

CICC

HK$14.7

Buy

23.32%

Upside

Reiterated

11/01/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$15

Buy

25.84%

Upside

Reiterated

10/31/25

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$12.1

Sell

1.51%

Upside

Reiterated

09/08/25

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$14.3

Buy

19.97%

Upside

Reiterated

08/29/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$17

Buy

42.62%

Upside

Reiterated

07/10/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$13.73

Buy

15.18%

Upside

Reiterated

05/06/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$13.8→HK$12.3

Buy

3.19%

Upside

Reiterated

04/07/25

Shanghai Pharmaceuticals Holdings (2607:HK) (FJLLF) PT Lowered to HK$12.30 at CLSACLSA analyst John Yung lowered the price target on Shanghai Pharmaceuticals Holdings (2607:HK) (OTC: FJLLF) to HK$12.30 (from HK$13.80) while maintaining a Outperform (2) rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Citi

Not Ranked

Citi

HK$14.2

Buy

19.13%

Upside

Reiterated

11/03/25

Citi Sticks to Their Buy Rating for Shanghai Pharmaceuticals Holding Co (SHPMF)

Owen Mediport

TR | OpenAI - 4o

HK$13.5→HK$13

Buy

9.06%

Upside

Reiterated

11/01/25

AI Generated ArticleAI Generated Article

Unknown Analyst

CICC

Not Ranked

CICC

HK$14.7

Buy

23.32%

Upside

Reiterated

11/01/25

Unknown Analyst

UBS

Not Ranked

UBS

HK$15

Buy

25.84%

Upside

Reiterated

10/31/25

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$12.1

Sell

1.51%

Upside

Reiterated

09/08/25

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$14.3

Buy

19.97%

Upside

Reiterated

08/29/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$17

Buy

42.62%

Upside

Reiterated

07/10/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$13.73

Buy

15.18%

Upside

Reiterated

05/06/25

Unknown Analyst

CLSA

Not Ranked

CLSA

HK$13.8→HK$12.3

Buy

3.19%

Upside

Reiterated

04/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai Pharmaceuticals Holding Co

1 Month

xxx

Success Rate

1/3 ratings generated profit

Average Return

-3.20%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -3.20% per trade.

3 Months

xxx

Success Rate

1/3 ratings generated profit

Average Return

-2.90%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -2.90% per trade.

1 Year

Owen MediportTR | OpenAI - 4o

Success Rate

1/3 ratings generated profit

Average Return

-2.90%

reiterated a buy rating 7 days ago

Copying Owen Mediport's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -2.90% per trade.

2 Years

xxx

Success Rate

1/3 ratings generated profit

Average Return

-2.90%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -2.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2607 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2607 has received 10 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. 2607 average Analyst price target in the past 3 months is 14.07.

Each month's total comprises the sum of three months' worth of ratings.

2607 Financial Forecast

2607 Earnings Forecast

Next quarter’s earnings estimate for 2607 is HK$0.23 with a range of HK$0.11 to HK$0.35. The previous quarter’s EPS was HK$0.21. 2607 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 2607 has Preformed in-line its overall industry.

2607 Sales Forecast

Next quarter’s sales forecast for 2607 is HK$72.93B with a range of HK$71.98B to HK$73.87B. The previous quarter’s sales results were HK$80.29B. 2607 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 2607 has Preformed in-line its overall industry.

2607 Stock Forecast FAQ

What is HK:2607’s average 12-month price target, according to analysts?

Based on analyst ratings, Shanghai Pharmaceuticals Holding Co Ltd Class H’s 12-month average price target is 14.07.

What is HK:2607’s upside potential, based on the analysts’ average price target?

Shanghai Pharmaceuticals Holding Co Ltd Class H has 18.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Shanghai Pharmaceuticals Holding Co Ltd Class H a Buy, Sell or Hold?

Shanghai Pharmaceuticals Holding Co Ltd Class H has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.

What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s share price target?

The average share price target for Shanghai Pharmaceuticals Holding Co Ltd Class H is 14.07. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$14.99 ,and the lowest forecast is HK$12.10. The average share price target represents 18.01% Increase from the current price of HK$11.92.

What do analysts say about Shanghai Pharmaceuticals Holding Co Ltd Class H?

Shanghai Pharmaceuticals Holding Co Ltd Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Shanghai Pharmaceuticals Holding Co Ltd Class H?

To buy shares of HK:2607, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Shanghai Pharmaceuticals Holding Co (2607) Stock Forecast & Price Target

2607 Analyst Ratings

2607 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Shanghai Pharmaceuticals Holding Co

2607 Analyst Recommendation Trends

2607 Financial Forecast

2607 Earnings Forecast

2607 Sales Forecast

2607 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts